Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 84

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 84
---
.08 and the dilution per share to new investors purchasing shares in this offering by $0.02 assuming the number of securities offered by us as set forth on the cover page of this prospectus remains the same, and after deducting the placement agent fees and estimated offering expenses payable by us. A $0.10 decrease in the assumed public offering price of $0.269 per share, which is the last reported sale price of our common stock on The Nasdaq Capital Market on February 6, 2025, would result in a decrease in our as adjusted net tangible book value per share after this offering by approximately $0.08 and the dilution per share to new investors purchasing shares in this offering by $0.02 assuming the number of securities offered by us as set forth on the cover page of this prospectus remains the same, and after the placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of securities to be issued in this offering. Each increase of 10 million Units offered by us would increase our as adjusted net tangible book value per share by $0.01 and the dilution per share to new investors purchasing securities in this offering by $0.01 assuming that the assumed public offering price remains the same, and after deducting the placement agent fees and estimated offering expenses payable by us. Each decrease of 10 million Units offered by us would decrease our as adjusted net tangible book value per share by $0.02 and the dilution per share to new investors purchasing securities in this offering by $0.02 assuming that the assumed public offering price remains the same, and after deducting the placement agent fees and estimated offering expenses payable by us. The information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined between us and Dawson James at pricing. The foregoing discussion and table do not give effect to (i) the adjustment to the conversion price of the Company’s Series A Preferred Stock and related warrants to $ as a result of this offering due to the anti-dilution provisions contained in such Series A Preferred Stock and warrants, (ii) the issuance of the Stock Awards in the amount of 2,200,000 shares of restricted shares of common stock to be issued to certain directors and officers of the Company, subject to the closing of this offering, and (iii) any exercise of the Series Warrants or conversion of the Series B Preferred Stock underlying the Series Warrants.

46

Further